Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.140
-0.090 (-7.32%)
At close: Apr 1, 2025, 4:00 PM
1.274
+0.134 (11.74%)
After-hours: Apr 1, 2025, 4:38 PM EDT
Marker Therapeutics Employees
Marker Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 59 or -88.06% compared to the previous year.
Employees
8
Change (1Y)
-59
Growth (1Y)
-88.06%
Revenue / Employee
$823,885
Profits / Employee
-$1,341,414
Market Cap
12.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MRKR News
- 8 hours ago - Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - GlobeNewsWire
- 1 day ago - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 3 months ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 3 months ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire
- 3 months ago - Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit - GlobeNewsWire